MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Agenus Net Income 2011-2026 | AGEN
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Agenus
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.08 M | -232 M | -257 M | -231 M | -28.7 M | -183 M | -108 M | -160 M | -121 M | -127 M | -87.9 M | -42.5 M | -30.1 M | -11.3 M | -23.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.08 M | -257 M | -110 M |
Quarterly Net Income Agenus
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63.9 M | -30 M | -26.4 M | - | -67.2 M | -54.8 M | -63.5 M | - | -64.5 M | -73.4 M | -70.9 M | - | -56.7 M | -49.2 M | -50.6 M | - | 177 M | -84 M | -54.4 M | -37.7 M | -51.6 M | -48.2 M | -45.3 M | -30.9 M | -46.3 M | -51.9 M | 17.4 M | -48.8 M | -33.7 M | -25.2 M | -54.3 M | -35 M | -36.8 M | -31.7 M | -17.1 M | -26.1 M | -40.8 M | -28.3 M | -31.8 M | -15.6 M | -13.1 M | -40.4 M | -18.7 M | -26 M | -8.11 M | -8.04 M | -357 K | -5.78 M | -7.32 M | -11.1 M | -5.84 M | -5.44 M | -5.73 M | -6.92 M | 6.77 M | -6.02 M | -5.53 M | -5.76 M | -5.96 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 177 M | -84 M | -25.5 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-27 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
MannKind Corporation
MNKD
|
5.86 M | $ 3.56 | 24.48 % | $ 1.09 B |  USA |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Bio-Techne Corporation
TECH
|
73.4 M | $ 47.41 | -16.36 % | $ 7.47 B | USA |
 |
United Therapeutics Corporation
UTHR
|
1.33 B | $ 596.76 | 4.29 % | $ 26.4 B | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-106 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
10.3 B | - | - | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | USA |
 |
INmune Bio
INMB
|
-45.9 M | $ 1.52 | -1.3 % | $ 37.6 M | USA |
 |
Exelixis
EXEL
|
783 M | $ 48.7 | 9.64 % | $ 13.2 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
226 M | $ 21.48 | -3.89 % | $ 3.56 B | USA |
 |
Fortress Biotech
FBIO
|
6.82 M | - | - | $ 71.1 M | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
-22.7 M | $ 3.15 | 1.19 % | $ 655 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.83 M | - | - | $ 5.51 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-186 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-43.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 24.17 | 3.2 % | $ 3.08 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-49.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
-120 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-30.4 M | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-582 M | $ 55.08 | 5.15 % | $ 4.95 B |  Schweiz |
 |
Avenue Therapeutics
ATXI
|
-2.91 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-288 M | $ 1.7 | 3.66 % | $ 452 M | Britain |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Завод ДИОД
DIOD
|
37.2 M | - | - | - | Russia |